Iptacopan is an innovative, first-in-class oral small molecule that reversibly inhibits factor B—a crucial serine protease in the alternative pathway of the complement system. By targeting this point ...

Some of the greatest advancements in modern medicine started with a scientist taking a risk to boldly pursue new areas of research. For scientists at Alexion — a leading biotech company dedicated to ...

Achillion Pharmaceuticals, Inc. ACHN announced that it has started a phase I study on its first orally administered small molecule complement factor D inhibitor, ACH-4471. The randomized, ...

NEW HAVEN, Conn., & AMSTERDAM--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Complement Pharma today announced a partnership to co-develop the preclinical C6 complement inhibitor ...